Oxyphenbutazone Anhydrous

CHEMBL1228 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

324.4 g/mol

LogP

2.7

Phase

4

An anhydrous form of oxyphenbutazone, sharing the same therapeutic uses.

分子量

324.4000 g/mol

LogP

2.70

TPSA

60.90 Å²

Lipinski 五规则

符合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O

InChI

InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3

Molecular Formula

C19H20N2O3

HBD / HBA

1 / 3

可旋转键数

5

重原子数

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

An anhydrous form of oxyphenbutazone, sharing the same therapeutic uses.

Yes, Oxyphenbutazone Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1228. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4641. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Oxyphenbutazone Anhydrous 在 PillFYI 上

结构

快速数据

分子式: C19H20N2O3

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.